Tata Elxsi launches AnaTel for AI-native medtech software

AnaTel is a practical healthcare-AI application because it targets regulatory software development rather than diagnosis hype. Tata Elxsi says the platform, co-developed with OpenAna, helps medical-device and software-as-a-medical-device companies accelerate software development, generate regulatory-grade documentation, and reduce development cycle times by up to 60%. The launch is tied to DeviceTalks Boston 2026 and responds to rising regulatory expectations around AI-enabled device software, including FDA draft guidance and Europe's MDCG 2025-26 requirements for lifecycle documentation, traceability, and validation evidence. This matters because medtech AI moves slowly when engineering artifacts and regulatory artifacts live in disconnected tools. The key question is whether AnaTel can maintain auditability and validation rigor while using autonomous engineering agents inside regulated product development.

Key details: Tata Elxsi, AnaTel, OpenAna, May 27, 2026, AI-native medtech software, SaMD, regulatory-grade documentation, up to 60% cycle-time reduction.

Continue swiping for more AI Brief stories.